Saturday, 28 January 2023

More approaches to design of covalent inhibitors of SARS-CoV-2 main protease

›
<< previous | I’ll pick up from the previous post on design covalent inhibitors of SARS-CoV-2 main protease (structure and chart num...
Wednesday, 25 January 2023

Assessment of chemical probes: response to Practical Fragments

›
<< previous | next >> I had originally intended to look at permeability in this post but I do need to respond to Dan Erlanson’...
Thursday, 19 January 2023

Some approaches to design of covalent inhibitors of SARS-CoV-2 main protease

›
<< previous | next >> I last posted on Covid-19 early in 2021 and quite a lot has happened since then. Specifically, a number...
Monday, 2 January 2023

Assessment of chemical probes

›
| next >> I’ll be taking a look at some of the criteria, specifically structural alerts, by which chemical probes are assessed and he...
2 comments:
Sunday, 24 July 2022

HB Donor Fragment Selection Themes

›
[This post was updated on 11-Dec-2024 to reflect the publication of the 'HBDs in drug design' preprint as the K2022 article] In th...
Friday, 1 April 2022

Enthalpic fragments

›
<< previous || next >> Enthalpy-driven binding has been presented as a rationale for screening fragments although some have ar...
Tuesday, 12 January 2021

Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32

›
<< previous || next >> It’s been ages since my last COVID-19 post (How not to repurpose a 'drug') and I’ll kick blog...
1 comment: